D-1 Bisphosphonate Bone Metastases Trials Proportion of Patients With Any SRE § (12, 010) Patients, % TreatmentN 3 mo6 mo9 mo12 mo Pamidronate Study 12.

Slides:

Advertisements

Similar presentations

Università Campus Bio-Medico

Advertisements

Advances and Emerging Therapy for Lung Cancer

Treatment in Advanced Non-Small Cell Lung Cancer.

Oncology The study of cancer. What is cancer? Any malignant growth or tumor caused by abnormal and uncontrolled cell division May be a tumor but it doesn’t.

Metastatic bone tumor Maher swaileh.

British Association of Urological Surgeons Metastatic Prostate Cancer Guidelines.

Bisphosphonates – A review

Prof. Robert Coleman, MD, FRCP Cancer Research Centre

Advances in the Management of Skeletal Related Events/Bone Metastases in Prostate Cancer Robert Dreicer, M.D., M.S., FACP, FASCO Chair Dept of Solid Tumor.

Lung Cancer Overview MaXiaoBiao Yun nan biotherapy center.

19th Annual NOCR Meeting Session I: Breast Cancer

Giving Induction Radiation in Addition to Chemotherapy Is Not Associated with Improved Survival of NSCLC Patients with Operable Mediastinal Nodal Disease.

Basics of Pediatric Oncology Margret E. Merino, MD Pediatric Hematology/Oncology WRAMC.

The Role of Palliative Radiotherapy for Patients with Cancer John Childs Radiation Oncologist Auckland District Health Board 20 th June 2012.

1Stopeck A et al. Proc SABCS 2010;Abstract P

Renal Safety of Zoledronic Acid in Patients With Breast Cancer.

Denosumab in bone metastasis of cancer and hypercalemia Supervisor: 趙大中大夫 Reporter: 郭政裕總醫師.

“Fighting Cancer: It’s All We Do.” ™. Restoring Quality of Life And Managing Side Effects Ulka Vaishampayan M.D. Chair, GU Multidisciplinary team Associate.

1 Ipriflavone in the Treatment of Postmenopausal Osteoporosis Randomized placebo-controlled, 4-year study conducted Europe 475 postmenopausal white women,

LUNG CANCER Dr.Mohammadzadeh. Lung cancer is the leading cancer killer in the United States. Every year, it accounts for 30% of all cancer deaths— more.

1 Phase II trial of sequential gemcitabine and carboplatin followed by paclitaxel as first-line treatment of advanced urothelial carcinoma Presented by.

Hormone Refractory Prostate Cancer A Regulatory Perspective of End Points to Measure Safety and Efficacy of Drugs Hormone Refractory Prostate Cancer Bhupinder.

Adult Medical-Surgical Nursing Musculo-skeletal Module: Bone Tumours.

A daganat-terápia alapjai Diagnosis –Histopathology –Tumor markers Cell surface markers (CD20, CD34…) Genetic markers (BRCA-1,Philadelphia chromosome)

Design of Clinical Trials for Select Patients With a Rising PSA following Primary Therapy Anthony V. D’Amico, MD, PhD Professor of Radiation Oncology Harvard.

NDA ZD1839 for Treatment of NSCLC FDA Review Division of Oncology Drug Products.

CC39/11-1 ZOMETA ® in Prostate Cancer and Solid Tumors Other Than Prostate Cancer and Breast Cancer: Placebo-Controlled Trials Matthew Smith, MD, PhD Massachusetts.

Validity of more than 30Gy radiation therapy for long-surviving patients with painful bone metastases E.Katayama 1,2, H.Okada 1, I.Asakawa 2, T.Tamamoto.

Treatment for metastatic bladdercancer (chemotherapy&radiotherapy) Dr.Mina Tajvidi oncologist.

CC10-1 ZOMETA ® in Breast Cancer and Multiple Myeloma: Pamidronate-Controlled Trial (010) James Berenson, MD Cedars-Sinai Medical Center Los Angeles, California.

CE-1 IRESSA ® Clinical Efficacy Ronald B. Natale, MD Director Cedars Sinai Comprehensive Cancer Center Ronald B. Natale, MD Director Cedars Sinai Comprehensive.

Change in Anatomic Distribution of Relapses with Accelerated Chemotherapy in Ewing Sarcoma RB Womer, AR Weiss, DC West, MD Krailo, PS Dickman, B Pawel,

The treatment of metastatic squamous cell carcinoma (SCCA) of the anal canal: A single institution experience P. Pathak, B. King, A. Ohinata, P. Das, C.H.

Core Benefit/Risk (CR)

Zometa for Patients with Bone Metastases Overview and Review of Study 010 Grant Williams, M.D. Medical Team Leader Division of Oncology Drug Products.

Which bisphosphonate? How long do you give it for? What about Denosumab? What is the most effective method of preventing bone disease in patients with.

Cancer, Exercise & Bone Health

AVADO TRIAL David Miles Mount Vernon Cancer Centre, Middlesex, United Kingdom A randomized, double-blind study of bevacizumab in combination with docetaxel.

IN-1 Oncologic Drugs Advisory Committee Bethesda, Maryland January 31, 2002 C.

Table 1. Characteristics of patients and the results of the log-rank test of prognostic factors Median (range) No. of patients No. of CRPC Median progression.

Evaluating the Effects of Zoledronic Acid on Overall Survival in Newly Diagnosed Patients with Multiple Myeloma: Results of the Medical Research Council.

Classroom Feud: Learning About Cancer Skin Cancer Breast Cancer Prostate Cancer Colo-rectal Cancer Lung Cancer What are the 5 most.

Lenalidomide Maintenance After Stem-Cell Transplantation for Multiple Myeloma: Follow-Up Analysis of the IFM Trial Attal M et al. Proc ASH 2013;Abstract.

1 Risk Benefit and Conclusions George Sledge, MD Indiana University School of Medicine.

REGULATORY HISTORY of ZOMETA and AREDIA JAW OSTEONECROSIS (ONJ) Oncologic Drug Advisory Committee March 4, 2005 Nancy S. Scher, M.D.

CON - 1 Conclusions C David R. Parkinson Vice President, Global Head, Clinical Research and Development Novartis Pharmaceuticals Corporation.

Zometa for Prostate Cancer Bone Metastases Protocol 039 Amna Ibrahim, M.D. Oncology Drug Products FDA.

3. How do you intend to resolve the issue?. Approach to the patient Assure patient’s safety! Talk the patient out of committing suicide – Remind him that.

Bone matters in lung cancer T. Brodowicz, K. O’Byrne & C. Manegold Annals of Oncology 23: 2215–2222, 2012 R3 김승민 /Prof 정재헌.

Date of download: 6/23/2016 From: Relative Effectiveness of Osteoporosis Drugs for Preventing Nonvertebral Fracture Ann Intern Med. 2008;148(9):

Bone Health Secondary Breast Cancer

Prof. Jae Heon, Jeong/R2 Cheol Hyun, Lee J of Clinical oncology, Vol 31 Number 4, Feb.1, 2013.

The role of bisphosphonates in the treatment of bone metastases of genitourinary tumors Nuno Gil WHAT YOU HAVE TO KNOW XIV WORKSHOP ON ONCOLOGICAL UROLOGY.

CCO Independent Conference Highlights

Campos M et al. Proc EHA 2013;Abstract B2009.

Campos M et al. Proc EHA 2013;Abstract B2009.

EVOLUZIONE DEL RAPPORTO COSTO/EFFICACIA DELLA

Local Consolidative Therapy in Oligometastatic NSCLC With No Progression on First-line Systemic Treatment CCO Independent Conference Coverage* of the 2016.

Prognosis of younger patients in non-small cell lung cancer

Alena Kreychman Xofigo.

Radiotherapy for Metastatic Spinal Cord Compression

Rossi A et al. Proc ASCO 2011;Abstract 8008.

Epidemiology and Treatment Costs of Bone Metastases from Lung Cancer: A French Prospective, Observational, Multicenter Study (GFPC 0601) Chantal Decroisette,

Skeletal Morbidity in Men with Prostate Cancer: Quality-of-Life Considerations throughout the Continuum of Care Fred Saad, Carl Olsson, Claude C. Schulman

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Overall survival in the IFCT trial comparing a single agent therapy arm (vinorelbine or gemcitabine) and the doublet carboplatin plus weekly paclitaxel.

Bisphosphonates Can Prevent Skeletal Complications of Malignant Bone Disease from Prostate Cancer and Renal Cell Carcinoma Fred Saad European Urology.

Manfred Wirth, Peter Iversen, David McLeod, William See

New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer Noel W. Clarke European Urology Supplements

Bisphosphonate Use in Patients with Lung Cancer and Bone Metastases: Recommendations of a European Expert Panel Filippo De Marinis, MD, Wilfried Eberhardt,

Presentation transcript:

D-1 Bisphosphonate Bone Metastases Trials Proportion of Patients With Any SRE § (12, 010) Patients, % TreatmentN 3 mo6 mo9 mo12 mo Pamidronate Study 12 Pam 90 mg Placebo ZOMETA ® Study 010 ZOMETA 4 mg ZOMETA 8/4 mg Pam 90 mg §Intent-to treat.

D-2 Bisphosphonate Bone Metastases Trials Demographic and Prognostic Variables (12, 010) Pamidronate Study 12 ZOMETA ® Study 010 PamZOMETAZOMETA Pam 90 mgPlacebo4 mg8/4 mg 90 mg Variable N = 198N = 179N = 183N = 160N = 167 Age, yr Mean ± s.d.64.1 ± ± ± ± ± Median Time from initial diagnosis to Visit 2, mo Mean ± s.d.30.5 ± ± ± ± ± Median

D-3 Bisphosphonate Bone Metastases Trials Proportion of Patients With Pathologic Fractures § (12, 010) Pamidronate Study 12: Proportion of patients with pathologic fracture in the 3 mo prior to study entry Time from diagnosisWithout pathologicWith pathologic to study entryNfractures, %fractures, %  6 mo > 6 mo ZOMETA ® Study 010: Proportion of pamidronate patients with pathologic fracture Time from diagnosis Patients, % to study entryN3 mo6 mo9 mo13 mo  6 mo > 6 mo §Intent-to treat.

D-4 Patients With Any SRE up to End-of-Core by Race (010, 011, 039) Patients, n/N (%) StudyZOMETA ® ZOMETAPam 90 mg/ numberRace4 mg8/4 mgplacebo 010N = 561N = 524N = 555 White225/493 (46)206/443 (47)234/484 (48) Black10/34 (29)22/42 (52)13/43 (30) Other13/34 (38)14/39 (36)10/28 (36) 011N = 257N = 266N = 250 White91/229 (40)85/238 (36)103/226 (46) Black4/15 (27)4/15 (27)4/12 (33) Other2/13 (15)3/13 (23)4/12 (33) 039N = 214N = 221N = 208 White64/178 (36)69/186 (37)77/172 (45) Black4/24 (17)7/19 (37)8/19 (42) Other3/12 (25)9/16 (56)7/17 (41) 54

D-5 ZOMETA ® Efficacy in Bone Metastases Prostate cancer (039) Solid tumors –PC/BC (011) Breast cancer and multiple myeloma (010) N = HCM (036, 037)

D-6 Solid Tumors – PC/BC Antineoplastic Therapies After Start of Study Drug (011) Patients, n (%) ZOMETA ® ZOMETA 4 mg8/4 mgPlacebo Antineoplastic therapy N = 254N = 265N = Any192(75.6)184(69.4)181(73.3) Carboplatin74(29.1)58(21.9)65(26.3) Paclitaxel52(20.5)58(21.9)46(18.6) Gemcitabine hydrochloride39(15.4)28(10.6)25(10.1) Cisplatin37(14.6)46(17.4)41(16.6) PTT 8.2-4

D-7 Breast Cancer and Multiple Myeloma Frequency Distribution of Antineoplastic Regimens (010) (1) Patients, n (%) ZOMETA ® ZOMETAPam No. of 4 mg8/4 mg90 mg StratumregimenN = 563N = 524N = Multiple myeloma, n (5.9)10(6.3)11(6.6) 174(39.8)58(36.3)72(43.1) 243(23.1)43(26.9)41(24.6) 329(15.6)31(19.4)21(12.6) 417(9.1)11(6.9)12(7.2)  512(6.5)7(4.4)10(6.0) PTT 8.2-7

D-8 Breast Cancer and Multiple Myeloma Frequency Distribution of Antineoplastic Regimens (010) (2) Patients, n (%) ZOMETA ® ZOMETAPam No. of 4 mg8/4 mg90 mg StratumregimenN = 563N = 524N = Breast cancer with chemotherapy, n (1.7)5(3.0)6(3.4) 153(30.1)51(30.2)58(32.4) 261(34.7)65(38.5)56(31.3) 334(19.3)22(13.0)35(19.6) 411(6.3)17(10.1)16(8.9)  514(8.0)9(5.3)8(4.5) Breast cancer with hormonal therapy, n (1.5)1(0.5)3(1.4) 193(46.3)114(58.5)91(43.3) 259(29.4)48(24.6)69(32.9) 332(15.9)19(9.7)34(16.2) 47(3.5)7(3.6)8(3.8)  57(3.5)6(3.1)5(2.4) PTT 8.2-7

D-9 Solid Tumors – PC/BC Frequency Distribution of Antineoplastic Regimens (011) Patients, n (%) ZOMETA ® ZOMETA No. of 4 mg8/4 mgPlacebo StratumregimenN = 254N = 265N = Non small cell lung cancer, n (16.7)29(22.3)25(21.4) 150(41.7)65(50.0)67(57.3) 236(30.0)24(18.5)16(13.7) 39(7.5)6(4.6)5(4.3) 45(4.2)3(2.3)3(2.6)  50(0)3(2.3)1(0.9) Other solid tumors, n (31.3)52(38.5)41(31.5) 161(45.5)60(44.4)54(41.5) 222(16.4)17(12.6)29(22.3) 38(6.0)3(2.2)4(3.1) 41(0.7)3(2.2)1(0.8)  50(0)0(0)1(0.8) PTT 8.2-7

D-10 Solid Tumors –PC/BC Time to First SRE Deaths and Dropouts Considered SREs (011) Median time, P -value N (%) § daysvs placebo ZOMETA ® 4 mg257 (73) ZOMETA 8/4 mg266 (80) Placebo250 (82)85 §Kaplan-Meier estimate of the proportion at Month 9.

D-11 Breast Cancer and Multiple Myeloma Time to First SRE Deaths and Dropouts Considered SREs (010) Median time, P -value N (%) § daysvs Pam 90 mg ZOMETA ® 4 mg561 (58) ZOMETA 8/4 mg555 (59) Pam 90 mg524 (61)252 §Kaplan-Meier estimate of the proportion at Month 13.

D-12 Prostate Cancer Time to First SRE Deaths and Dropouts Considered SREs (039) Median time, P -value N (%) § daysvs placebo ZOMETA ® 4 mg214 (66) ZOMETA 8/4 mg221 (74) Placebo208 (73)221 §Kaplan-Meier estimate of the proportion at Month 15.

D-13 Cumulative Incidence Rate of SRE All Patients § (039) ZOMETA 4 mg ZOMETA 8/4 mg Placebo Median time, days ZOMETA® 4 mg NRP =.013 ZOMETA 8/4 mgNRP =.357 Placebo PTF p3 21 §Intent-to-treat. NR = Not reached.

D-14 Prostate Cancer Median Serum PSA Level (Observed) (039) ZOMETA 4 mg ZOMETA 8/4 mg Placebo ZOMETA® 4 mg ZOMETA 8/4 mg Placebo 039 PTF

D-15 Prostate Cancer Total Number of SREs (039) With 21-day window Without 21-day window ZOMETA ® ZOMETA 4 mg Placebo4 mgPlacebo SRE (+HCM) SRE Pathologic fracture Vertebral fracture Nonvertebral fracture Radiation to bone Surgery to bone Spinal cord compression Change to antineoplastic therapy Hypercalcemia Pro 011 PTT 9.2-6xx

D-16 Cumulative Incidence Rate of SRE All Patients § (011) ZOMETA 4 mg ZOMETA 8/4 mg Placebo Median time, days ZOMETA® 4 mg314P =.044 ZOMETA 8/4 mgNRP =.037 Placebo PTF p3 20 §Intent-to-treat. NR = not reached.

D-17 Solid Tumors –PC/BC Total Number of SREs (011) With 21-day window Without 21-day window ZOMETA ® ZOMETA 4 mg Placebo4 mgPlacebo SRE (+HCM) SRE Pathologic fracture Vertebral fracture Nonvertebral fracture Radiation to bone Surgery to bone Spinal cord compression Hypercalcemia Pro 011 PTT 9.2-6xx

D-18 Breast Cancer and Multiple Myeloma Total Number of SREs (010) With 21-day window Without 21-day window ZOMETA ® PamZOMETAPam 4 mg 90 mg4 mg 90 mg SRE (+HCM) SRE Pathologic fracture Vertebral fracture Nonvertebral fracture Radiation to bone Surgery to bone Spinal cord compression Hypercalcemia Pro 011 PTT 9.2-6xx